Company news
Mustang Bio, Inc. (NASDAQ:MBIO) news
Mustang Bio, Inc. news releases on 6ix. Latest, May 19, 2022: Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency…
Press releases — page 2
Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107
May 18, 2022
Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
May 11, 2022
Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress
May 11, 2022
Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting
May 2, 2022
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106, CD20-Targeted CAR T Therapy, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
April 24, 2022
Mustang Bio Announces Upcoming MB-106 CD20-Targeted CAR T Data Presentations
April 20, 2022
Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma
April 12, 2022
Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
April 3, 2022
Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
March 22, 2022
Mustang Bio to Participate in Three March 2022 Investor Conferences
March 9, 2022
Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children’s Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 8, 2022
Mustang Bio Completes a $75 Million Debt Financing with Runway Growth Capital
March 7, 2022
Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium
February 14, 2022
Mustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact Awards
February 7, 2022
Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted Patients
January 23, 2022
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
January 6, 2022
Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences
January 4, 2022
Mustang Bio Added to the NASDAQ Biotechnology Index
December 15, 2021
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
December 12, 2021
Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
December 8, 2021
Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
November 11, 2021
Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency
November 9, 2021
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
November 3, 2021
Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas
October 31, 2021
Mustang Bio to Participate in Chardan’s Virtual 5th Annual Genetic Medicines Conference
September 29, 2021
Mustang Bio Announces MB-101 (IL13Rα2‐targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences
September 27, 2021
Mustang Bio to Participate in Three September 2021 Investor Conferences
September 8, 2021
Mustang Bio Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights
August 15, 2021
Mustang Bio Collaborates with Mayo Clinic on Novel CAR T Technology
August 11, 2021
Mustang Bio Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants
August 1, 2021
Mustang Bio Awarded Massachusetts Life Sciences Center Tax Incentive
June 16, 2021
Mustang Bio to Present at the Raymond James Human Health Innovation Conference
June 15, 2021
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
June 10, 2021
Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
June 6, 2021
Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
May 17, 2021
Mustang Bio Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
May 13, 2021
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress
May 11, 2021
Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy
May 9, 2021
Mustang Bio to Participate in Chardan’s 5th Annual Genetic Medicines Manufacturing Summit
April 20, 2021
Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights
March 23, 2021
Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences
March 3, 2021
Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
February 25, 2021
Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
February 1, 2021
Mustang Bio to Participate in Three January 2021 Virtual Investor Conferences
January 4, 2021
Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
December 20, 2020
Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
December 6, 2020
Mustang Bio to Host Key Opinion Leader Call on MB-106 for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
November 30, 2020
Mustang Bio Announces Positive Opinion from the European Medicines Agency on Orphan Drug Designation for Its Lentiviral Gene Therapy for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)
November 23, 2020
Mustang Bio and Minaris Regenerative Medicine Sign Technology Transfer and GMP Manufacturing Agreement for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency
November 22, 2020
Mustang Bio Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights
November 5, 2020